Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients
- A. Åsberg, A. Hartmann, E. Fjeldså, S. Bergan, H. Holdaas
- Medicine
- American journal of transplantation : official…
- 1 November 2001
Atorvastatin is increasingly used as a cholesterol‐lowering agent in solid organ transplant recipients receiving cyclosporine A (CsA). However, the potential bilateral pharmacokinetic interaction… Expand
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
- I. Lunde, S. Bremer, +5 authors H. Christensen
- Biology, Medicine
- European Journal of Clinical Pharmacology
- 22 March 2014
PurposeTacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5. Several studies have demonstrated an association between the CYP3A5 genotype and Tac dose requirements.… Expand
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
- Pål Falck, N. T. Vethe, +4 authors H. Holdaas
- Medicine
- Nephrology, dialysis, transplantation : official…
- 15 October 2007
BACKGROUND
The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors and… Expand
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
- M. Brunet, T. van Gelder, +34 authors S. Bergan
- Medicine
- Therapeutic drug monitoring
- 2019
Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association… Expand
Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients
- R. Mandla, Pål-Dag Line, K. Midtvedt, S. Bergan
- Chemistry, Medicine
- Therapeutic drug monitoring
- 1 June 2003
Mycophenolic acid, the active moiety of mycophenolate mofetil, inhibits the enzyme inosine monophosphate dehydrogenase. The main metabolite, mycophenolic acid glucuronide, has no immunosuppressive… Expand
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts.
- S. Bergan, O. Bentdal, G. Sødal, A. Brun, H. Rugstad, O. Stokke
- Biology, Medicine
- Therapeutic drug monitoring
- 1 October 1997
Monitoring of azathioprine (AZA) therapy by the measurement of 6-thioguanine nucleotides (6-TGN) concentrations in red blood cells (RBC) may improve safety and ensure optimal immunosuppressive… Expand
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
- N. Picard, S. Bergan, +4 authors V. Haufroid
- Medicine
- Therapeutic drug monitoring
- 1 April 2016
Abstract: In association with therapeutic drug monitoring of immunosuppressive drugs, pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or, more interestingly to… Expand
Calcineurin Inhibitor‐Free Immunosuppression in Renal Allograft Recipients with Thrombotic Microangiopathy/Hemolytic Uremic Syndrome
- O. Øyen, E. H. Strøm, +5 authors I. B. Brekke
- Medicine
- American journal of transplantation : official…
- 1 February 2006
Thrombotic microangiopathy (TMA) and hemolytic uremic syndrome (HUS) represent serious threats to kidney allograft recipients.
Importance of hematocrit for a tacrolimus target concentration strategy
- Elisabet Størset, N. Holford, K. Midtvedt, S. Bremer, S. Bergan, A. Åsberg
- Medicine
- European Journal of Clinical Pharmacology
- 27 September 2013
PurposeTo identify patient characteristics that influence tacrolimus individual dose requirement in kidney transplant recipients.MethodsData on forty-four 12-h pharmacokinetic profiles from 29… Expand
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
- N. T. Vethe, R. Mandla, P. Line, K. Midtvedt, A. Hartmann, S. Bergan
- Chemistry, Medicine
- Scandinavian journal of clinical and laboratory…
- 1 January 2006
Objective. Mycophenolic acid (MPA) exerts its immunosuppression by inhibiting inosine 5′‐monophosphate dehydrogenase (IMPDH), depleting activated lymphocytes of guanine nucleotides and retarding… Expand